Shailesh Jain1, Thomas J Carmody1, Madhukar H Trivedi1, Carroll Hughes1, Ira H Bernstein1, David W Morris1, Graham J Emslie1, A John Rush2. 1. Drs. Jain, Trivedi, Hughes, Morris, and Emslie are with the Department of Psychiatry and Drs. Carmody and Rush are with the Departments of Psychiatry and Clinical Sciences at The University of Texas Southwestern Medical Center at Dallas; and Dr. Bernstein is with The University of Texas at Arlington. 2. Drs. Jain, Trivedi, Hughes, Morris, and Emslie are with the Department of Psychiatry and Drs. Carmody and Rush are with the Departments of Psychiatry and Clinical Sciences at The University of Texas Southwestern Medical Center at Dallas; and Dr. Bernstein is with The University of Texas at Arlington.. Electronic address: john.rush@utsouthwestern.edu.
Abstract
OBJECTIVE: This study compared the psychometric properties of the Children's Depression Rating Scale-Revised (CDRS-R) and the Montgomery-Asberg Depression Rating Scale (MADRS) in children with major depressive disorder. METHOD: Children (N = 96; ages 8 to 11 years inclusive) with nonpsychotic major depressive disorder were enrolled. Participants were part of a multisite, outpatient, randomized, placebo-controlled, 9-week trial of fluoxetine (10 mg/day for the first week and 20 mg/day thereafter). The CDRS-R and MADRS were completed based on clinician interviews with both parents and children. Classic test theory and item response theory analyses were conducted. RESULTS: The MADRS and CDRS-R total scores were correlated at baseline (r = 0.51) and at study exit (r = 0.85). Cronbach's alpha was .86 (CDRS-R) and .82 (MADRS) at exit. The effect sizes for change from baseline to exit between the fluoxetine and placebo groups were 0.78 (CDRS-R) and 0.61 (MADRS). There was agreement between the CDRS-R and MADRS in the declaration of treatment response (50% improvement from baseline to exit) in 84.2% of children. Test information function favored the CDRS-R. CONCLUSIONS: The CDRS-R showed greater effect size for differentiating drug and placebo and better test information than the MADRS in this study of depressed children.
RCT Entities:
OBJECTIVE: This study compared the psychometric properties of the Children's Depression Rating Scale-Revised (CDRS-R) and the Montgomery-Asberg Depression Rating Scale (MADRS) in children with major depressive disorder. METHOD:Children (N = 96; ages 8 to 11 years inclusive) with nonpsychotic major depressive disorder were enrolled. Participants were part of a multisite, outpatient, randomized, placebo-controlled, 9-week trial of fluoxetine (10 mg/day for the first week and 20 mg/day thereafter). The CDRS-R and MADRS were completed based on clinician interviews with both parents and children. Classic test theory and item response theory analyses were conducted. RESULTS: The MADRS and CDRS-R total scores were correlated at baseline (r = 0.51) and at study exit (r = 0.85). Cronbach's alpha was .86 (CDRS-R) and .82 (MADRS) at exit. The effect sizes for change from baseline to exit between the fluoxetine and placebo groups were 0.78 (CDRS-R) and 0.61 (MADRS). There was agreement between the CDRS-R and MADRS in the declaration of treatment response (50% improvement from baseline to exit) in 84.2% of children. Test information function favored the CDRS-R. CONCLUSIONS: The CDRS-R showed greater effect size for differentiating drug and placebo and better test information than the MADRS in this study of depressedchildren.
Authors: M S Gould; R King; S Greenwald; P Fisher; M Schwab-Stone; R Kramer; A J Flisher; S Goodman; G Canino; D Shaffer Journal: J Am Acad Child Adolesc Psychiatry Date: 1998-09 Impact factor: 8.829
Authors: Thomas J Carmody; A John Rush; Ira Bernstein; Diane Warden; Stephen Brannan; Daniel Burnham; Ada Woo; Madhukar H Trivedi Journal: Eur Neuropsychopharmacol Date: 2006-06-12 Impact factor: 4.600
Authors: Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Carroll W Hughes; Madhukar H Trivedi; Joseph Cleaver; Tracy L Greer; Graham J Emslie; Beth Kennard; Shauna Dorman; Tyson Bain; Judy Dubreuil; Conrad Barnes Journal: Ment Health Phys Act Date: 2009-12
Authors: Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch Journal: J Child Psychol Psychiatry Date: 2020-02-04 Impact factor: 8.982
Authors: Benedetto Vitiello; David A Brent; Laurence L Greenhill; Graham Emslie; Karen Wells; John T Walkup; Barbara Stanley; Oscar Bukstein; Betsy D Kennard; Scott Compton; Barbara Coffey; Mary F Cwik; Kelly Posner; Ann Wagner; John S March; Mark Riddle; Tina Goldstein; John Curry; Lisa Capasso; Taryn Mayes; Sa Shen; S Sonia Gugga; J Blake Turner; Shannon Barnett; Jamie Zelazny Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-09-30 Impact factor: 8.829
Authors: Carly Johnco; Joseph F McGuire; Nicole M McBride; Tanya K Murphy; Adam B Lewin; Eric A Storch Journal: J Affect Disord Date: 2016-04-23 Impact factor: 4.839
Authors: Greg Clarke; Christina R Sheppler; Alison J Firemark; Andreea M Rawlings; John F Dickerson; Michael C Leo Journal: Contemp Clin Trials Date: 2020-02-28 Impact factor: 2.226
Authors: Johanna M Meyer; Joseph P H McNamara; Adam M Reid; Eric A Storch; Gary R Geffken; Dana M Mason; Tanya K Murphy; Regina Bussing Journal: Child Psychiatry Hum Dev Date: 2014